Blueprint Medicines has patented a method for treating RET-altered non-small cell lung cancer by administering a selective RET inhibitor like Compound 1. The method involves oral administration of specific doses of the inhibitor once daily. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of February 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of ret-altered non-small cell lung cancer
A recently granted patent (Publication Number: US11872192B2) outlines a method for treating patients with rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC) by orally administering daily doses of Compound 1 or its salt. The patent specifies dosages of 200 mg, 300 mg, or 400 mg of Compound 1 for effective treatment. The method targets NSCLC cases with a RET-gene rearrangement, particularly RET fusions involving genes such as CLIP1, PIBF1, BCR, and others listed in the claims.
Furthermore, the patent details the treatment of metastatic NSCLC cases that have previously undergone platinum-based or cabozantinib/vandetanib treatments. Dosage specifics are provided for different scenarios, with 300 mg or 400 mg of Compound 1 being administered once daily for optimal therapeutic outcomes. The administration of Compound 1 or its salt is primarily in solid dosage forms like tablets or capsules, ensuring ease of use and compliance for patients undergoing this treatment regimen. The patent aims to address the specific needs of patients with RET-altered NSCLC, offering a targeted and potentially effective therapeutic approach for this subset of lung cancer cases.
To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
